EGFR and neoplasm: The shGLI-1 group showed no significant tumor size reduction, indicating that GLI-1 may not significantly influence EGFR-TKI erlotinib response, contrary to previous research suggesting GLI-1 suppression enhances sensitivity to erlotinib [35], suggesting that GLI-1 may not directly influence EGFR signaling in lung cancer cells.